Šakaitytė Austėja, Česnavičiūtė Inga, Raudonis Tadas
Clinic of Infectious Diseases and Dermatovenereology, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, 03101 Vilnius, Lithuania.
European Hidradenitis Suppurativa Foundation e.V., 06847 Dessau, Germany.
Clin Pract. 2024 Aug 27;14(5):1696-1706. doi: 10.3390/clinpract14050135.
Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition characterized by inflammatory lesions, often leading to scarring. Managing HS can be difficult, requiring biological therapy, specifically adalimumab.
A retrospective study was conducted on patients diagnosed with HS and treated with the TNF-α inhibitor adalimumab. Data from 21 patients were included in this study. International Hidradenitis Suppurativa Severity Score System (IHS4); Dermatology Life Quality Index (DLQI); pain intensity according to the Visual Analogue Scale (VAS); and number of nodules, abscesses, and fistulas were assessed.
Notably, 47.62% of patients achieved Hidradenitis Suppurativa Clinical Response. The mean number of inflamed nodules decreased from 5.62 ± 4.12 to 3 ± 3.46, abscesses decreased from 1.76 ± 2.63 to 0.81 ± 1.4, and fistulas decreased from 2.62 ± 1.86 to 2 ± 1.9 ( < 0.05). The IHS4 score decreased from 19 ± 10.78 to 12.62 ± 11.13 ( = 0.001), DLQI from 15.76 ± 7.73 to 7.43 ± 7.76 ( < 0.001), and VAS from 6.69 ± 1.56 to 3.64 ± 2.65 ( < 0.001). There was a significant difference in the baseline IHS4 scores between patients who had prior surgery with a mean score of 23.86 ± 9.4 versus non-surgical patients with a mean IHS4 score of 9.29 ± 5.53 ( = 0.001).
About half of HS patients responded positively to adalimumab treatment; the use of the drug reduces inflammatory lesions, and pain, and improves quality of life.
化脓性汗腺炎（HS）是一种慢性炎症性皮肤病，其特征为炎症性病变，常导致瘢痕形成。管理HS可能很困难，需要生物疗法，特别是阿达木单抗。
对诊断为HS并接受肿瘤坏死因子-α抑制剂阿达木单抗治疗的患者进行回顾性研究。本研究纳入了21例患者的数据。评估国际化脓性汗腺炎严重程度评分系统（IHS4）；皮肤病生活质量指数（DLQI）；根据视觉模拟量表（VAS）评估的疼痛强度；以及结节、脓肿和瘘管的数量。
值得注意的是，47.62%的患者实现了化脓性汗腺炎临床缓解。炎症结节的平均数量从5.62±4.12减少到3±3.46，脓肿从1.76±2.63减少到0.81±1.4，瘘管从2.62±1.86减少到2±1.9（P<0.05）。IHS4评分从19±10.78降至12.62±11.13（P = 0.001），DLQI从15.76±7.73降至7.43±7.76（P<0.001），VAS从6.69±1.56降至3.64±2.65（P<0.001）。既往接受过手术的患者基线IHS4评分平均为23.86±9.4，与未接受手术的患者（IHS4评分平均为9.29±5.53）之间存在显著差异（P = 0.001）。
约一半的HS患者对阿达木单抗治疗反应良好；该药物的使用减少了炎症性病变和疼痛，并改善了生活质量。
